Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis
- PMID: 25005891
- PMCID: PMC4143664
- DOI: 10.1016/j.jpba.2014.06.018
Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis
Abstract
Background: Topical microbicidal agents are being actively pursued as a modality to prevent HIV viral transmission during sexual intercourse. Quantification of antiretroviral agents in specimen sources where antiviral activity is elicited is critical, and drug measurements in cervicovaginal fluid can provide key information on local drug concentrations. Two antiretroviral drugs, dapivirine and maraviroc, have gained interest as vaginal microbicidal agents, and rugged methods are required for their quantification in cervicovaginal secretions.
Methods: Cervicovaginal fluid spiked with dapivirine and maraviroc were applied to ophthalmic tear strips or polyester-based swabs to mimic collection procedures used in clinical studies. Following sample extraction and the addition of isotopically labeled internal standards, samples were subjected to liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis using a Waters BEH C8, 50mm×2.1mm, 1.7μm particle size column, on an API 4000 mass analyzer operated in selective reaction monitoring mode. The method was validated according to FDA Bioanalytical Method Validation guidelines.
Results: Due to the disparate saturation capacity of the tested collection devices, the analytical measuring ranges for dapivirine and maravirocin cervicovaginal fluid on the ophthalmic tear strip were 0.05-25ng/tear strip, and 0.025-25ng/tear strip, respectively. As for the polyester-based swab, the analytical measuring ranges were 0.25-125ng/swab for dapivirine and 0.125-125ng/swab for maraviroc. Dilutional studies were performed for both analytes to extended ranges of 25,000ng/tear strip and 11,250ng/swab. Standard curves were generated via weighted (1/x(2)) linear or quadratic regression of calibrators. Precision, accuracy, stability and matrix effects studies were all performed and deemed acceptable according to the recommendations of the FDA Bioanalytical Method Validation guidelines.
Conclusions: A rugged LC-MS/MS method for the dual quantification of dapivirine and maraviroc in cervicovaginal fluid using two unique collection devices has been developed and validated. The described method meets the criteria to support large research trials.
Keywords: Antiretroviral; Cervicovaginal fluid; Dapivirine; Maraviroc; Validation.
Copyright © 2014 Elsevier B.V. All rights reserved.
Figures




Similar articles
-
Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk.Clin Biochem. 2020 Aug;82:66-72. doi: 10.1016/j.clinbiochem.2019.12.005. Epub 2019 Dec 13. Clin Biochem. 2020. PMID: 31843664 Free PMC article. Clinical Trial.
-
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.J Pharm Biomed Anal. 2016 Nov 30;131:333-344. doi: 10.1016/j.jpba.2016.08.016. Epub 2016 Sep 4. J Pharm Biomed Anal. 2016. PMID: 27632783
-
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Clin Chim Acta. 2014 Apr 20;431:198-205. doi: 10.1016/j.cca.2014.02.008. Epub 2014 Feb 19. Clin Chim Acta. 2014. PMID: 24561264 Free PMC article.
-
Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory.Clin Chem. 2010 Aug;56(8):1234-44. doi: 10.1373/clinchem.2009.138602. Epub 2010 May 28. Clin Chem. 2010. PMID: 20511452 Review.
-
Advancement in Analytical Strategies for Quantification of Biomarkers with a Special Emphasis on Surrogate Approaches.Crit Rev Anal Chem. 2023;53(7):1515-1530. doi: 10.1080/10408347.2022.2035210. Epub 2022 Feb 9. Crit Rev Anal Chem. 2023. PMID: 35138951 Review.
Cited by
-
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).AIDS Res Hum Retroviruses. 2022 Apr;38(4):269-278. doi: 10.1089/AID.2021.0096. Epub 2021 Sep 14. AIDS Res Hum Retroviruses. 2022. PMID: 34384282 Free PMC article. Clinical Trial.
-
Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk.Clin Biochem. 2020 Aug;82:66-72. doi: 10.1016/j.clinbiochem.2019.12.005. Epub 2019 Dec 13. Clin Biochem. 2020. PMID: 31843664 Free PMC article. Clinical Trial.
-
Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.J Acquir Immune Defic Syndr. 2020 Feb 1;83(2):135-139. doi: 10.1097/QAI.0000000000002244. J Acquir Immune Defic Syndr. 2020. PMID: 31929401 Free PMC article. Clinical Trial.
-
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897. J Acquir Immune Defic Syndr. 2016. PMID: 26565716 Free PMC article. Clinical Trial.
-
Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01930-18. doi: 10.1128/AAC.01930-18. Print 2019 Mar. Antimicrob Agents Chemother. 2019. PMID: 30602513 Free PMC article. Clinical Trial.
References
-
- Global report: UNAIDS report on the global AIDS epidemic 2012. 2012 http://www.unaids.org/en/resources/publications/2012.
-
- Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infections. Lancet. 2010;376:49–62. - PubMed
-
- Weber J, Tatoud R, Fidler S. Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS. 2010;24:S27–S39. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials